Clinical Trials Browser

Phase 2/3 × sintilimab × Gastrointestinal × Clear all

NCT06977061 2025-05-16

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

Phase 2/3 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT05250843 2023-10-13

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma

NCT05002686 2021-08-24

Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

Phase 2/3 Unknown

Gastrointestinal

Stomach Neoplasms

NCT04167293 2021-03-23

ISBRT01

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03794440 2021-01-22

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Phase 2/3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular